Plus Therapeutics (NASDAQ: PSTV) presented encouraging data from a retrospective analysis of the CNSide® Cerebrospinal Fluid (CSF) Assay Platform at the 2025 Society for Neuro-Oncology (SNO) / American Society of Clinical Oncology (ASCO) CNS Metastases Conference in Baltimore, Maryland.
Key Findings from the CNSide® Analysis
The results highlight the potential of CNSide® to transform how physicians diagnose, monitor, and treat leptomeningeal metastases (LM):
-
Quantification of LM Over Time: CNSide® enables physicians to measure disease burden longitudinally.
-
Mutation Monitoring: The assay tracks real-time changes in the expression of multiple targetable mutations.
-
Treatment Decision Support: Findings suggest that CNSide® may help initiate LM treatment earlier, adapt therapies to dynamic tumor biology, and enable more personalized cancer therapy.
Why This Matters
Leptomeningeal metastases remain a serious complication of advanced cancers, with limited treatment options and poor patient outcomes. Current diagnostic methods are often insufficient in guiding therapy. By providing a real-time, actionable molecular profile of LM, CNSide® offers physicians a powerful tool to optimize patient care and accelerate innovation in neuro-oncology.
Commitment to Patients and Innovation
This presentation underscores Plus Therapeutics’ leadership in CNS cancers and metastases research. Together with CNSide Diagnostics, we continue to advance new technologies and clinical approaches that improve treatment options for patients with brain and central nervous system cancers.
Read the full press release here.
#PlusTherapeutics #CNSide #LeptomeningealMetastases #LM #CNSMetastases #NeuroOncology #BrainCancer #CancerResearch #CancerTherapy #PersonalizedMedicine #ClinicalTrials #PSTV #ASCO #SNO #SNOASCO2025
Recent Comments